PFE周末出所谓的坏消息耐人寻味
http://biz.yahoo.com/ap/061202/pfizer_cholesterol_drug.html?.v=3
从图形上看，PFE在10/31-11/03日在$26.50支撑线上强势盘整。11/07星期二突破并收在$27.25支撑线之上。但后来表明这是一个短暂的短线假突破。随后11/08-11/10接连三个跳空阴线放量破位完成最后一洗。然后11/13开始V型反转，连续温和带量拉高，11/20-11/29强势窄幅调整，11/30-12/01连续两个高开高走略微带量突破。图形上看非常强势。PFE/MRK过去一周的强势带动了制药板DRG大阳线W型突破345后两阳夹一阴窄幅强势盘整。
目前PFE处于刚有效突破$27.50支撑/阻力线。由于在10/31和11/09有两个80M日成交量打底，从11/13日星期一开始到12/01星期五为止的三周十三个半交易日强势上涨构成的非常标准的以11/10星期五为轴心的V型右半部只是在突破时温和放量，特别是在11/29的高开低走中阴线，11/30和12/01两天的高开高走连续强势突破$27.50也都没有显著放量。尤其PFE这一段时间盘前成交很活跃，应该是主力之间大规模换手的迹象。
周末出这种消息耐人寻味，因为这种消息不会（立刻）造成股价的短线波动，主力之间对这个消息早就知道。图形上看PFE短线有调整要求。最大的可能是12/04星期一走成低开高走下探主要支撑线的反转阳线。股价最差有可能下探$27，但应不会跌破11/27的最低价$26.75，过去6个交易日这一波的波谷。若日内5分钟图没有止跌迹象而跌到$26.50的话，则可以大胆抄底，因为$26.50会是强支撑：2006/08突破$26.50前回撤过，2006/11跌下$26.50立刻拉了回来。最不济的情况是$26.50抄进去被套，但$25.50，11/13日的急剧上涨起涨点，会是极强支撑！
PFE历史上在强势上涨至2006/07月底准备突破$26.50创新年高时出现过两周10个交易日的调整。看看这次在突破$28.50创新年高之前是不是也要这样？PFE两年年高阻力线是$29。
制药板DRG看来短线会继续震荡。
目前SP500指数的向下调整是由金融板主导。石油板撑盘。金融板BKX可能会再跌一天下探112从而短线组成三连跌再探112支撑线。金融板短线止跌时，制药板窄幅横盘震荡微调，石油板连续走强后调整，共同维持SP500指数在1385以上或1380-1400之间的调整。
Pfizer Ends Cholesterol Drug Development
Saturday December 2, 10:39 pm ET
Pfizer Cutting Off Development of Cholesterol Drug That Was to Be Star of Drugmaker's Pipeline
The world's largest drugmaker said it was told Saturday that an independent board monitoring a study for torcetrapib, a drug that raises levels of HDL, or what's commonly known as good cholesterol, recommended that the work end because of "an imbalance of mortality and cardiovascular events."
Pfizer said it is asking all clinical investigators conducting trials to warn patients to stop taking the drug immediately.
The news is devastating to Pfizer, which had been counting on the drug to revitalize stagnant sales that have been hurt by numerous patent expirations on key products.
Just two days ago, Pfizer had said it hoped to file an application with the Food and Drug Administration for approval of torcetrapib by the second half of next year. But on Saturday, the company said the loss of the drug will not affect its financial guidance for 2006.
New York-based Pfizer had expected to sell Torcetrapib in combination with Lipitor, which lowers bad cholesterol and is the company's -- and the world's -- best-selling drug.
According to Pfizer spokesman Paul Fitzhenry, 82 patients taking the combination of torcetrapib died, compared to 51 deaths in the arm of the study where patients were taking Lipitor alone. Each arm of the study had 7,500 patients. Pfizer said that the study didn't raise any questions about Lipitor's safety.
There already had been concerns about Torcetrapib because a study showed it caused an increase in blood pressure. In raising its earnings guidance for the year Thursday the company emphasized that it has 242 research programs and other promising drugs in the pipeline, but analysts remained focused on Torcetrapib and said Pfizer would struggle without it.
Patent expirations will cost the company $14 billion in annual sales between 2005 and 2007, the company said. Lipitor, which had $12.2 billion in sales last year, may lose patent protection by 2010.
Dr. Philip Barter, chairman of the steering committee overseeing the study, said in Pfizer's release that the findings of the data safety monitoring board Torcetrapib were a surprise "in light of prior study results."
"We believed that the study was coming along as expected, and this new information was totally unexpected and disappointing, given the potential benefits of this drug," said Barter, Director of the Heart Research Institute in Australia.
